Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT05931367
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Interventions
Name:
Retatrutide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
TimeFrame:
Baseline, Week 68
Description:
Measure:
Percent Change from Baseline in Body Weight
TimeFrame:
Baseline, Week 68
Description:
Trial Information
NCT ID
NCT05931367
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025